Reversing the New Anticoagulants
|
|
|
- Basil Chambers
- 10 years ago
- Views:
Transcription
1 Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1
2 Roadmap for today Characteristics of novel anticoagulants Approach to the bleeding patient Specific reversal agents UCSF guidelines Scope of Problem Prevalence atrial fibrillation 3.03 million in million by 2050 VTE = 900K/yr in US 1-2% of adults take warfarin Warfarin 1920s Outbreak hemorrhagic disease in cattle in northern US and Canada 1933 Isolated by Karl Link 1948 Rodenticde 1954 Approved in humans WARF-arin Wisconsin Alumni Research Foundation Coumarin, plant molecule in sweet clover 2
3 Warfarin Disadvantages Bridging Drug and food interactions Long half-life Close monitoring required Why New Anticoagulants? Rapid onset/shorter half-life Fewer drug and no food interactions No lab monitoring Equivalent to warfarin Prevention of stroke, VTE Bleeding rates New Anticoagulant Disadvantages Limited experience treating bleeding No proven reversal agent No monitoring What s in a name? Direct Thrombin Inhibitors (DTIs) Novel Oral Anticoagulants (NOACS) Target Specific Oral Anticoagulants (TSOACS) 3
4 Roadmap for today Characteristics of novel anticoagulants Approach to the bleeding patient Specific reversal agents UCSF Guidelines New Anticoagulants Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) New Anticoagulants Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Dabigatran Indications FDA approved Stroke prevention in non-valvular afib Under FDA review VTE prophylaxis in hip or knee replacement Approved in Europe/Canada 4
5 Dabigatran Dose Stroke prevention 150 mg, po bid Renal insufficiency 75 mg, po bid DVT prophylaxis 220 mg, po qd Dabigatran Mechanism Direct Thrombin (Factor IIa) inhibitor Blocks conversion of fibrinogen to fibrin Dabigatran Pharmacology Dabigatran etexilate = inactive pro-drug Rapidly absorbed Active form binds active site of thrombin Inhibits free and clot-bound thrombin 5
6 Dabigatran Pharmacokinetics Predictable Rapid onset Peak plasma level at 2 hours Half-life hours Dabigatran Pharmacokinetics No food interactions, few drug interactions Fixed dosing can be used No need for routine monitoring or dose adjustment Dabigatran Metabolism Dabigatran Metabolism 85% excreted via the kidneys Use caution with renal dysfunction Low protein binding Eliminated by hemodialysis NOT metabolized by p450 system Substrate of efflux transporter P-glycoprotein Inducers (e.g., rifampin) reduce effect Inhibitors (e.g., verapamil) increase effect 6
7 Dabigatran Metabolism New Anticoagulants Decreased effect with P-gP inducers Rifampin Increased effect with P-gP inhibitors Dronedarone Ketoconazole, Itraconazole Verapamil Amiodarone Quinidine Clarithromycin Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) FACTOR Xa INHIBITORS Rivaroxaban (Xarelto )Apixaban (Eliquis ) Indications Rivaroxaban/Apixaban Stroke prevention in non-valvular atrial fib Rivaroxaban only VTE prophylaxis post-joint replacement DVT/PE prophylaxis and treatment 7
8 Rivaroxaban and Apixaban Dose Non-valvular afib Rivaroxaban and Apixaban Mechanism Selective, direct, factor Xa inhibitors Rivaroxaban, 20 mg po qd Apixaban, 5 mg po qd DVT/PE Rivaroxaban, 15 mg po qd DVT prophylaxis Rivaroxaban,10 mg po qd Rivaroxaban and Apixaban Pharmacology Highly protein bound Not easily dialyzed Few drug interactions Rivaroxaban and Apixaban Pharmacokinetics Similar to dabigatran Predictable Not affected by age, sex, body weight Fixed dose Peak at 2 3h Half life 7-14h 8
9 Rivaroxaban Excretion 2/3 rd renal 1/3 rd liver Dose adjusted for reduced CrCl Metabolism Apixaban Excretion 2/3 rd liver, biliary 1/3 rd renal Coagulation Assays Not routinely necessary Indications Major bleeding Overdose Emergent surgery Coagulation Assays Coagulation Assays Dabigatran Peak/trough ng/ml aptt Prolonged at >50 ng/ml Normal at 25 ng/ml Dabigatran aptt not useful Thrombin time If normal, dabigatran not present Thrombin time Prolonged at 3 ng/ml Normal at 1 ng/ml 9
10 Coagulation Assays Coagulation Assays Rivaroxaban/Apixaban Peak/trough ng/ml aptt Prolonged at 120 ng/ml Normal at 60 ng/ml Rivaroxaban/Apixaban Anti-factor Xa assay No assay for rivaroxaban available Ask for assay calibrated for enoxaparin Estimate of rivaroxaban/apixaban activity Roadmap for today Characteristics of novel anticoagulants Approach to the bleeding patient Specific reversal agents UCSF guidelines Approach to Bleeding Discontinue anticoagulant Compress Fluid replacement, transfusion 10
11 Approach to Bleeding Consider emergent reversal Intracranial Pericardial Intraspinal Hemorrhagic shock Drug overdose Emergency surgery Roadmap for today Characteristics of novel anticoagulants Approach to the bleeding patient Specific reversal agents UCSF guidelines Reversal Agents NO ROLE FOR VITAMIN K IN REVERSAL OF NEW ORAL ANTICOAGULANTS Reversal: Options Hemodialysis (dabigatran only) Prothombin complex concentrate (PCC) Recombinant Factor VIIa (rfviia) apcc (FEIBA ) 11
12 Reversal: Hemodialysis For reversing dabigatran Evidence 6 healthy volunteers w ESRD 62% removed after 2 hours 68% removed after 4 hours Two preparations Reversal: PCC Kcentra 4-factor PCC (II, VII, IX, X) Bebulin 3-factor PCC (II, IX, X) Rivaroxaban/apixaban too highly proteinbound for HD Stangier, 2010 Reversal: Specific Agents Reversal: Specific Agents Human studies Animal studies Specific Antidotes Human studies Animal studies Specific Antidotes 12
13 Reversal: Specific Agents Reversal: Human Studies Human studies 5 studies, Healthy volunteers Anticoagulants: dabigatran, rivaroxaban, apixaban Reversal agents PCC apcc rfviia Erenberg, 2011 Study design N=12 subjects Dabigatran or rivaroxaban po x 2.5 d Treated with PCC bolus iv Measured PT and ETP over 24 hours Outcome: clotting assays Reversal: Human Studies Erenberg, 2011 Findings PCC reversed PT, ETP in rivaroxaban treated patients PCC did not reverse dabigatran Reversal: Human Studies Marlu, 2012 Study design N=10 men Dabigatran or rivaroxaban po x 1 Collected blood samples Treated blood (PCC, rfviia, apcc) 13
14 Reversal: Human Studies Reversal: Human Studies Marlu, 2012 Findings Dabigatran rfviia most effective Rivaroxaban PCC most effective Khoo, 2013 Dabigatran+aPCC Study design N=8 subjects on dabigatran Blood treated with apcc Reversal: Human Studies Reversal: Human Studies Khoo, 2013 Findings apcc reversed dabigatran Dinklaar, 2013 Rivaroxaban+PCC Study Design N=9 subjects PCC added to rivaroxaban-treated samples Coagulation assays performed 14
15 Reversal: Human Studies Reversal: Human Studies Dinklaar, 2013 Rivaroxaban + PCC Findings mixed results PCC Normalized thrombin generation Did not normalize PT Dose of PCC required depended on type of assay Korber, 2013 Rivaroxaban + PCC/rFVIIa Study design N=10 subjects Blood samples treated with rivaroxaban Added PCC and rviia Performed clotting assays Reversal: Human Studies Human Studies: Summary Korber, 2013 Rivaroxaban + PCC/rVIIa Findings PCC had no effect on clotting tests rviia reversed PT and clotting factor time prolongation Dabigatran Reversed with apcc in 2/2 studies Rivaroxaban Reversed with PCC in 3/4 studies 15
16 Human studies: Limitations Reversal: Specific Agents Variable designs Healthy volunteers Reversal agents added to blood samples Clotting tests proxy for bleeding Human studies Animal studies Specific antidotes Reversal: Animal studies 6 studies, Anticoagulants: Dabigatran Rivaroxaban Apixaban Reversal agents PCC rfviia apcc (FEIBA ) Fibrinogen FFP Outcomes Clotting assays Bleeding Van Ryn, 2008 Study Design Rats infused w high dose dabigatran x 20 min Reversed with rfviia and apcc (FEIBA ) given iv Bleeding measured 5 min after tail incision 16
17 Van Ryn, 2008 Findings Both agents reduced bleeding time Neither agent reduced blood loss Zhou, 2011 Study Design Mice were treated with dabigatran po ICH induced Reversed with intravenous PCC Murine FFP rfviia Zhou, 2011 Findings N=96 mice PCC prevented hematoma expansion Murine FFP worked only with high dose dabigatran rfviia did not prevent hematoma expansion Godier, 2012 Study Design (n=83 rabbits) T=0 min, rivaroxaban iv T=1 min, procoagulant iv (PCC, rfviia) Hepatosplenic bleeding induced T=15 min, total blood loss recorded 17
18 Godier, 2012 Findings Neither rfviia nor PCC reduced total blood loss Pragst, 2012 Study Design (n=28 rabbits) T=0 min, dabigatran iv T=5 min, PCC infusion T=10 min, kidney incision Pragst, 2012 Findings PCC reduced blood loss, bleeding time Dose dependent Perzborn, 2013 Study Design rats T=0 min, rivaroxaban iv T=5 min, bleeding induced T=6 min, reversal iv (PCC, apcc, rfviia) 18
19 Perzborn, 2013 Findings rats n=7-12/group All agents reduced bleeding time PCC apcc rfviia Perzborn, 2013 Study Design baboons (n=7) T=0 min, rivaroxaban infusion T=30 min, reversal agent Experimental forearm incision Bleeding time measured Perzborn, 2013 Findings apcc and rviia both reduced bleeding time apcc from twice normal to normal rfviia from 2.5 normal to 1.7 normal Martin, 2013 Study design T=0, simultaneous apixaban bolus and reversal agent bolus T=20 min hepatosplenic section T=30 min, blood loss measured 19
20 Summary of Animal Studies Martin, 2013 Findings rfviia partially corrected bleeding time PCC, rfviia, fibrinogen did NOT reverse blood Dabigatran PCC reversed dabigatran in 3/3 animal studies Rivaroxaban and Apixaban PCC, apcc, rfviia reversed rivaroxaban in 1/3 studies Animal Studies: Limitations Reversal: Specific Agents Wide variability in study design Different doses Different species Different outcomes (coagulation assays, bleeding time, blood loss) Human studies Animal studies Specific antidotes Human clotting factors behave differently in non-humans 20
21 Reversal: Specific Antidotes Reversal: Specific Antidotes r-antidote (PRT064445) adabi-fab PER977 r-antidote (PRT064445) Antidote for rivaroxaban Recombinant protein Binds Xa inhibitor site Reduced blood loss in animal models Not tested in humans Lu, 2013 Reversal: Specific Antidotes Reversal: Specific Antidotes adabi-fab Monoclonal antibody Antidote for dabigatran Reversed anticoagulant assays in rats PER977 Small synthetic molecule Directly binds Xa and IIa Reverses dabigatran, rivaroxaban, apixaban Schiele, 2013 Laulicht,
22 Summary Specific Antidotes Three promising agents None FDA-approved in humans yet Roadmap for today Characteristics of novel anticoagulants Approach to the bleeding patient Specific reversal agents UCSF guidelines UCSF Guidelines UCSF Guidelines Caveat: No proven reversal agents or antidotes 22
23 UCSF Guidelines General Principles Discontinue drug Hemostasis Hemodynamic support Reverse other antithrombotic drugs UCSF Guidelines Consider Hemodialysis (dabigatran only) Activated charcoal UCSF Guidelines If other measures fail Assess thrombotic risk In past 6 wks MI CVA, TIA DVT/PE Severe PVD UCSF Guidelines If all measures fail apcc (FEIBA ) to reverse dabigatran PCC (Kcentra ) to reverse rivaroxaban/apixaban 23
24 FEIBA and Kcentra Cautions Increase risk of thromboembolism Reversal is OFF-LABEL Weigh risk/benefit Blood products Kcentra contains heparin Roadmap for today Characteristics of novel anticoagulants Approach to the bleeding patient Specific reversal agents UCSF guidelines 24
Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS [email protected] Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
Disclosure. Warfarin
Disclosure No conflicts of interest to disclose Reversal Strategies for Novel Oral Anticoagulants Noelle de Leon, PharmD, BCPS Critical Care Pharmacist, Department of Pharmaceutical Services Assistant
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
DOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
Comparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
Impact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
Dabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
Making Sense of the Newer Anticoagulants
Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant
Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
Traditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
The management of cerebral hemorrhagic complications during anticoagulant therapy
The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
TSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
FDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
CONTEMPORARY REVERSAL OF ANTICOAGULATION
CONTEMPORARY REVERSAL OF ANTICOAGULATION Michael S. McHale, M.D., F.A.C.P. Avera Medical Group Hematology & Oncology Medications Coumadin / Warfarin Unfractionated Heparin Low Molecular Weight Heparin
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
Time of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
Novel oral anticoagulants (NOACs): novel problems and their solutions
Novel oral anticoagulants (NOACs): novel problems and their solutions Martin H. Ellis MD Hematology Institute and Blood Bank Meir Medical Center January 2013 OVERVIEW NOACs in clinical use Review of pivotal
Anticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA [email protected] Dabigatran and Rivaroxaban:
Objectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
How To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
New Oral Anticoagulants
Laboratory Monitoring of New Oral Anticoagulants.....What you need to know Rita Selby MD Medical Director, Coagulation Laboratories Uniersity Health Network & Sunnybrook HSC Uniersity of Toronto The 15
The Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
Comparative Anticoagulation
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
New Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
MANAGING BLEEDING IN THE
MANAGING BLEEDING IN THE SETTING OF NEW ANTICOAGULANTS: HOW DO OLD METHODS MEASURE UP? Michelle Zeller MD Clinical Hematology Fellow November 5th, 2011 A FRIDAY NIGHT ON-CALL WITH DR. B. LUD Very keen
LAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
Management for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
Rivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
New Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
DISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak [email protected] University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
New Anticoagulation Agents and Their Reversal Agents. Objectives. Background 12/21/2015
New Anticoagulation Agents and Their Reversal Agents Jay Hazelcorn, Pharm.D. PGY-1 Pharmacy Resident Broward Health Medical Center Objectives Review the pharmacology, indications, and place in therapy
3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
Oral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center [email protected] August 2012 Oral Anticoagulant
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
The Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
Coagulation issues and bridging. Joost van Veen Consultant Haematologist - STHFT
Coagulation issues and bridging Joost van Veen Consultant Haematologist - STHFT new oral anticoagulants NOAC New oral anticoagulants NOAC Novel oral anticoagulants NOAC Non vitamin K oral anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
How To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
Novel Anticoagulants
Novel Anticoagulants Kathleen Ozsvath, MD Associate Professor of Surgery, Albany Medical Center Partner, The Vascular Group, Albany, NY Chief of Vascular Services, Samaritan and St. Mary s Hospital, Troy,
The author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 [email protected] This presentation will discuss unlabeled and investigational use of products The author
Reversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
Critical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
Blood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
Recommendation for the Reversal of Novel Anticoagulants in Emergent Situations
Lauren Edwards PharmD Candidate 2016 Truman Medical Center, Lakewood Preceptor: Dr. Melissa Gabriel June 11, 2015 Recommendation for the Reversal of Novel Anticoagulants in Emergent Situations Background
New Oral Anticoagulants for VTE, A-fib, and ACS
New Oral Anticoagulants for VTE, A-fib, and ACS KCUMB Fall CME 2014 September 18, 2014 Schoen W. Kruse, Ph.D. Assistant Dean Associate Professor of Pharmacology KCUMB An 82 y/o male presents to the ED
New anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
QUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University
QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A
Novel Anticoagulants
Novel Anticoagulants Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting Disorders University of Minnesota
How does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really getting antagonized?
Anticoagulation reversal Vitamin K antagonists and New Oral Anticoagulants Robert Orman, MD Warfarin How does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
To assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs).
MANAGEMENT OF BLEEDING IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To assist clinicians
Disclosures. I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis
TSOACs: Glee Lenoir, Pharm D. Pharmacy Clinical Coordinator The Medical Center Nursing Conference March 2015 Disclosures I have served as an advisory board member, consultant, speaker, and / or received
2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
Anticoagulants. Denver Health April 12, 2011
New Oral Anticoagulants Rebecca Hanratty, MD Denver Health April 12, 2011 Overview Why we need alternatives to warfarin Review of the 3 new oral anticoagulants Results from major trials: Thromboprophylaxis
What to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille
What to do in case of hemorragia with NOAC? L Camoin Jau Service d Hématologie APHM Marseille Disclosure Boehringer Bayer Daishi Sanofi BMS Pharmacodynamic and kinetic properties of new oral anticoagulants.
New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS
New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS Clinical Pharmacy Specialist, Cardiology September 2012 Objectives Describe the mechanisms of action for novel
NOACs 2013: Evolving Anticoagulation Options. Erik Yeo MD University Health Network University of Toronto
NOACs 2013: Evolving Anticoagulation Options Erik Yeo MD University Health Network University of Toronto Objectives Clinical overview the new oral anticoagulants and their management issues Rivaroxaban
New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D.
New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D. Introduction Since the 1950 s, the only orally available anticoagulant has been the vitamin K antagonist
New Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
How To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
Anticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
Advances in An+coagula+on
Advances in An+coagula+on Laurajo Ryan PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Aus+n College of Pharmacy UTHSCSA School of Medicine Pharmcotherapy Research Educa+on
Hemostasis and Thrombosis Update for Primary Care Providers. Primary Care Medicine: Principles and Practice. Topic Outline
Hemostasis and Thrombosis Update for Primary Care Providers Primary Care Medicine: Principles and Practice Topic Outline Non-Vitamin K antagonist Oral Anti-Coagulants NOACs Background on these agents Use
Reversing novel anticoagulants to divert catastrophe SEAN P. WILSON, MD DEPARTMENT OF EMERGENCY MEDICINE HENRY FORD HOSPITAL, DETROIT, MI
Reversing novel anticoagulants to divert catastrophe SEAN P. WILSON, MD DEPARTMENT OF EMERGENCY MEDICINE HENRY FORD HOSPITAL, DETROIT, MI Novel anticoagulants? Dabigatran (Pradaxa) Stroke and systemic
Cardiology Medications New Drugs, New Guidelines
Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 Cardiology Medications Objectives The attendee will understand Indications,